<DOC>
	<DOCNO>NCT00645411</DOCNO>
	<brief_summary>The present study first study design evaluate safety , tolerability immunogenicity cell culture-derived influenza vaccine healthy child adolescent age 3 17 year . A step-down approach utilized reactogenicity safety assess child adolescent 9 17 year age ( Cohort 1 ) prior enrol additional child adolescents 9 17 year age ( Cohort 2 ) child 3 8 year age ( Cohort 3 ) .</brief_summary>
	<brief_title>Pediatric Safety Immunogenicity Study Cell-Culture Derived Egg-based Subunit Influenza Vaccines Healthy Children Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Subjects age 9 17 year ( Cohorts 1 2 ) 3 8 year ( Cohort 3 ) , whose parents/legal guardian give write informed consent prior study entry . Assent obtain subject accord age requirement ECs/IRBs ; 2 . In good health determine : 1. medical history , 2. physical examination , 3. clinical judgment Investigator ; 3 . Able comply study procedure available clinic visit telephone call schedule study . 1 . Any serious disease , : 1. cancer , 2. autoimmune disease ( include rheumatoid arthritis ) , 3. diabetes mellitus , 4. chronic pulmonary disease , 5. acute progressive hepatic disease , 6. acute progressive renal disease ; 2 . History anaphylaxis serious reaction follow administration vaccine , hypersensitivity egg , egg protein , chicken feather , influenza viral protein , neomycin , polymyxin , vaccine component , chemically related substance , component potential packaging material ; 3 . Known suspected impairment/alteration immune function , include : 1. use immunosuppressive therapy systemic corticosteroid know associated suppression hypothalamicpituitaryadrenal ( HPA ) axis chronic use inhale highpotency corticosteroid within 60 day prior Visit 1 , 2. cancer chemotherapy , 3. receipt immunostimulants within 60 day prior Visit 1 , 4. receipt parenteral immunoglobulin preparation , blood product , and/or plasma derivative within 3 month prior Visit 1 plan full length study , 5. know HIV infection HIVrelated disease ; 4 . History GuillainBarré syndrome ; 5 . Bleeding diathesis ; 6 . Surgery plan study period ; 7 . Receipt another investigational agent within 90 day , completion safety followup period another study , whichever longer , prior enrollment unwilling refuse participation another clinical study end study ; 8 . Receipt another vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior Visit 1 ; 9 . Laboratoryconfirmed influenza disease within 6 month prior Visit 1 ; 10 . For subject age 3 8 year old , ever receive two dos influenza vaccine one influenza season ; 11 . Receipt influenza vaccine within 6 month prior Visit 1 ; 12 . Experienced temperature 38.0°C [ 100.4°F ] ) and/or acute illness within 3 day prior Visit 1 ; 13 . Pregnant nursing mother ; 14 . Female childbearing potential sexually active use acceptable birth control measure least 2 month prior study entry plan use acceptable birth control measure 3 week follow vaccination refuse urine pregnancy test prior enrollment . Oral , inject , insert implanted hormonal contraceptive , diaphragm condom spermicidal agent intrauterine device consider acceptable form birth control ; 15 . Children research staff live research staff directly involve clinical study . Research staff individual direct study subject contact , indirect contact study subject , study site personnel access study document contain subject information . This would include receptionist , person schedule appointment make screen call , regulatory specialist , laboratory technician , etc . ; 16 . Any condition , opinion Investigator , might interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Flu</keyword>
	<keyword>Cell Culture-Derived</keyword>
	<keyword>Egg-Derived</keyword>
	<keyword>Healthy Children</keyword>
	<keyword>Healthy Adolescents</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Trivalent</keyword>
	<keyword>Inactivated</keyword>
	<keyword>Vaccination</keyword>
</DOC>